Research Site

Odessa, Texas 79902

4 studies enrolling now · 17 studies all time

What they study most

Anemia, Cardiovascular Disease, Chronic Kidney Disease, Chronic Kidney Disease and Hypertension, Congestive Heart Failure, Diabetes Mellitus, Non-Insulin-Dependent, Diverticulitis, Dyslipidemia, Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD), Heart Failure, Heart Failure and Impaired Kidney Function, High Risk for Cardiovascular Event

Studies at this site

• A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy — Recruiting now
• Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations — Recruiting now
• A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event — Recruiting now
• Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function — Recruiting now
• A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. — Running, not enrolling
• Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD — Stopped early
• Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial) — Completed
• Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk — Completed
• RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial — Completed
• Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction — Completed
• Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia — Completed
• A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease — Completed
• Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events — Completed
• A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes — Completed
• A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease — Completed
• Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications — Completed
• Asacol Acute Diverticulitis(DIVA)Study — Completed